Best Practices in the Care of People with Drug-Resistant TB that has Expanded Resistance: An Overview


Jennifer Furin, MD., PhD

Harvard Medical School, Department of Global Health and Social Medicine



Objectives

 To present approaches to the care of people with complex drug resistance patterns, including diagnosis, management, and use of newer compounds



Individualized approaches still needed for some populations

- "Real-world" performance always less successful than that seen in trials;
- Toxicity and drug discontinuation must be managed by programs and clinicians;
- Drug resistance <u>always</u> exists and may be selected for during sub-optimal treatment;
- Lack of systematic baseline resistance testing can further amplify drug resistance;
- Ongoing transmission of drug-resistant strains is a well-documented occurrence with DR-TB.



EUROPEAN RESPIRATORY JOURNAL RESEARCH LETTER R. PERUMAL ET AL.

Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis

To the Editor:

Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org

Received: 15 April 2023 Accepted: 22 Oct 2023 Bedaquiline is a novel antimycobacterial agent for drug-resistant tuberculosis (TB) and is classified as a World Health Organization (WHO) group A drug due to its excellent clinical efficacy, high bactericidal activity, and potent sterilising effect [1]. The introduction of bedaquiline into treatment regimens has enabled short-course all-oral multidrug-resistant TB (MDR-TB) regimens and the shortening of drug-susceptible TB treatment [2, 3].

Bedaquiline targets F_1F_0 -ATP synthase to impair $Mycobacterium\ tuberculosis\ (Mtb)$ ATP synthesis and exerts other incompletely characterised bactericidal effects [4]. Variants in the target atpE and atpB genes and off-target mutations in mmpR5, mmpL5 and pepQ have been associated with bedaquiline resistance [5, 6]. We performed a systematic review and meta-analysis to estimate the frequency of, and mutations associated with, baseline and acquired (treatment-emergent) bedaquiline resistance in clinical Mtb isolates.

The study protocol was registered in PROSPERO (CRD42022346547) and the PRISMA guidelines were followed for reporting of the review methods and findings. Systematic searches of MEDLINE/PubMed, Cochrane Central Register of Clinical Trials, and EMBASE were conducted through February 2023 for publications on phenotypic resistance of bedaquiline. We included studies which reported clinical Mtb isolates with bedaquiline resistance via minimum inhibitory concentration (MIC) values from patients with at least rifampicin-resistant TB. Given the suboptimal positive predictive value of resistance-associated variants for phenotypic resistance, our study only evaluated phenotypic resistance as defined by MIC thresholds. We excluded studies with MIC cut-offs inconsistent with WHO cut-offs, in vitro Mtb isolates not obtained from patients, or $\leqslant 3$ patients/isolates. Phenotypic bedaquiline resistance was defined by critical concentrations of $1 \mu g$ -mL $^{-1}$ by MGIT method or $0.25 \mu g$ -mL $^{-1}$ by broth microdilution or 7H11

Global Situation: Bedaquiline Resistance

- Baseline 2-3% among newly diagnosed people and as high as 7% in some settings;
- Emergence during treatment usually around 2-3% in general treatment cohorts;
- Rv0678 mutations most common but can see pepQ mutations as well:
- Not likely to have cartridge-based testing anytime soon:
- Cross-resistance with CFZ common (? universal?);
- In a population of patients on BDQ-containing regimens in Cape Town who still had a positive culture at 4 months, 8% had baseline BDQ resistance and 47% acquired BDQ resistance over time;
- Risk factors included baseline FLQ resistance, prior exposure to CFZ, and four or fewer effective drugs in the regimen.

Global Situation: Other Drugs

INT J TUBERC LUNG DIS 27(7):567–569 © 2023 The Union http://dx.doi.org/10.5588/ijtld.22.0632



Linezolid resistance in patients with drug-resistant TB

Dear Editor,

Multidrug-resistant TB (MDR-TB) continues to be a global public health issue. Linezolid (LZD) has been shown to be one of the most effective drugs against MDR-TB.1 A meta-analysis of 12,030 patients showed treatment success was positively associated with LZD use (adjusted risk difference 0.15, 95% confidence interval [CI] 0.11-0.18) compared to not using the drug.² New treatment regimens containing bedaquiline (BDQ), pretomanid, LZD with or without moxifloxacin (BPaLM/BPaL) have been recommended by the WHO for MDR-TB programmes.3 Unfortunately, global resistance to LZD has been observed, especially in India, which has a high burden of MDR-TB.4-6 Potential risk factors to acquired LZD resistance are addition of LZD to a failing or inadequate regimen, or interruption of LZD due to adverse events or loss to follow-up.7 In a recent metaanalysis, pooled frequency of LZD resistance in clinical isolates of MDR-TB bacteria was reported to be 4.2%.4 However, the majority of the studies included in this analysis were from China and Turkey, with only one carried out in India.4 Here we report on the clinical/epidemiological profile and treatment outcome of patients with LZD resistance admitted to a Médecins Sans Frontières (MSF) clinic in Mumbai, India.

clinic, patients' laboratory investigations and followup included GeneXpert testing (Cepheid, Sunnyvale, CA, USA), first-line and second-line line-probe assays, culture-based DST, chest radiographs (CXRs) and other relevant radiological examinations. Treatment lasted 20-22 months. A multidisciplinary team provided clinical and psychosocial support. Patients were followed up every month after enrolment and monthly sputum culture was done once treatment began. Treatment outcomes were defined according to national guidelines (cured, completed, failed, death, lost to follow-up).9 Unfavourable outcomes were defined as treatment failure or died. Risk factors for unfavourable treatment outcome were tested using multivariable logistic regression; risk factors with P < 0.2, in univariate analysis were included in the model. Cumulative incidence of the unfavourable treatment outcome was estimated using the Kaplan-

Between 2016 and 2020, 365 DR-TB patients were registered and LZD resistance was found in 19.7% (72/365). The median age of patients with LZD resistance was 28 years (interquartile range [IQR] 22–35); 53% (38/72) were male; 39% (28/72) were severely underweight (BMI-for-age Z-score of –3 for adolescents aged 11–17 years and a BMI of 16.5 kg/m² in adults), and 7% (5/72) had extrapulmonary TB.

- Meta-analysis showed pooled frequency of LZD resistance around 4.2%;
- High rates seen in some selected cohorts (i.e. 19.7% in MSF Mumbai);
- Delamanid and pretomanid with similar results: 1-4.4%;
- Higher pretomanid MICs in lineage 1 strains;
- Genetic mechanisms of resistance complex for all these drugs, limited phenotypic testing experience.




The BETTER Project

- Building Experience Treating Tuberculosis with Expanded Resistance;
- Volunteer group of front-line providers, impacted communities, TB programs, and civil society organizations;
- Goal is to share best practices and provide support to one another in how to best provide care for TB that has "expanded resistance"—community of practice;
- "Expanded resistance" includes resistance to BDQ, LZD, CFZ, or nitroimidazole

Best Practices for Clinical Management of Tuberculosis with Expanded Resistance

A Field Guide





First Edition, December 2024

Issues Covered by BETTER

- Optimizing DST;
- Informed consent and shared decision making;
- Regimen design;
- Holistic packages of support;
- Special populations;
- Pre-approval access to novel compounds;
- Post-exposure management for household contacts;
- Toxicity monitoring and management;
- Operational research considerations.

Figure 1: Components of Shared Decision Making

Patient input and experience: Clinician input and experience: · Current health and social status · Indications for screening, testing, prevention, Medical history and previous healthcare experience treatment, and follow-up · Short- and long-term health and treatment goals · Disease natural history, epidemiology, and prognosis; · Knowledge of medical conditions, treatment options, risks and benefits of initiating, deferring, or declining and prior treatment experience · Values and preferences · Recommended and alternative treatment and care · Limitations and barriers to healthcare and options and their benefits, limitations, and risks engagement in care · Available resources for support and assistance · Available financial resources and social support · Strategies for implementing various care and treatment options Open and respectful dialogue, clinician awareness, informed and collaborative evaluation of options **Shared decision-making**

Figure 1 taken from: New York State Department of Health. AIDS Institute HIV Guidelines. Shared Decision Making. August, 2023. Figure reprinted with express written permission from the New York State Department of Health.

Informed Consent and Shared Decision Making

Different Ways People Come into Care with "Expanded Resistance"



- Remote prior exposure to one or more agents;
- Currently on therapy and "not doing well"—how to define in terms of micro, clinical, and "interruptions";
- Currently on therapy and doing well but results come that show resistance;
- Contacts of these individuals.

Regimen Design: Standardized Approaches?

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Oral Regimens for Rifampin-Resistant, Fluoroguinolone-Susceptible Tuberculosis

L. Guglielmetti, U. Khan, G.E. Velásquez, M. Gouillou, A. Abubakirov, E. Baudin, E. Berikova, C. Berry, M. Bonnet, M. Cellamare, V. Chavan, V. Cox, Z. Dakenova, B.C. de Jong, G. Ferlazzo, A. Karabayev, O. Kirakosyan, N. Kiria, M. Kunda, N. Lachenal, L. Lecca, H. McIlleron, I. Motta, S.M. Toscano, H. Mushtaque, P. Nahid, L. Oyewusi, S. Panda, S. Patil, P.P.J. Phillips, J. Ruiz, N. Salahuddin, E.S. Garavito, K.I. Seung, E. Ticona, L. Trippa, D.E.V. Vasquez, S. Wasserman, M.L. Rich, F. Varaine, and C.D. Mitnick, for the endTB Clinical Trial Team*

ABSTRACT

The authors' full names, academic de- For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of at the Department of Global Health and shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.

We conducted a phase 3, multinational, open-label, randomized, controlled noninferiority trial to compare standard therapy for treatment of fluoroquinolonesusceptible, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). Participants were randomly assigned (with the use of Bayesian response-adaptive randomization) to receive one of five combinations or standard therapy. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was -12 percentage points.

grees, and affiliations are listed in the Appendix, Dr. Mitnick can be contacted at carole mitnick@hms.harvard.edu or Social Medicine, Harvard Medical School, 641 Huntington Ave., Rm. 3A05, Boston,

*A list of the members of the endTB Clinical Trial Team is provided in the Supplementary Appendix, available at NEIM.org.

MA 02115

Drs. Guglielmetti, Khan, and Velásquez and Drs. Varaine and Mitnick contributed equally to this article.

N Engl I Med 2025:392:468-82. DOI: 10.1056/NEIMoa2400327 Copyright © 2025 Massachusetts Medical Society.

- Very few regimens do not contain BDQ (or CFZ), LZD, FLQ;
- ? endTB regimen 5: DLM-CFZ-MFX-PZA in people with non-severe disease (but CFZ and BDQ cross resistance);
- ? MDR-FND: 9 DLM-LFX-LZD-PZA in people with non-severe disease;
- Be careful with BPal!!

Individual Regimen Design: Principles

GROUPS & STEPS	MEDICINE	
Group A: Include all three medicines	Levofloxacin <u>OR</u> Moxifloxacin	Lfx Mfx
	Bedaquiline ^{2,3}	Bdq
	Linezolid ⁴	Lzd
Group B:	Clofazimine	Cfz
Add one or both medicines	Cycloserine <u>OR</u> Terizidone	Cs Trd
Group C:	Ethambutol	Е
Add to complete the regimen and when	Delamanid ^{3,5}	Dlm
medicines from Groups A and B cannot be	Pyrazinamide ⁶	Z
used	Imipenem-cilastatin <u>OR</u> Meropenem ⁷	Ipm-Cln Mpm
	Amikacin (OR Streptomycin) ⁸	Am (S)
	Ethionamide <u>OR</u> Prothionamide ⁹	Eto Pto
	p-aminosalicylic acid9	PAS

- Very similar to WHO principles for designing individual regimens;
- 4-5 "likely effective drugs"—although regimen may have more than 4-5 drugs (and 4 drugs really only for non-severe disease);
- Most regimens will contain cycloserine (terizidone)
- Older drugs such as PAS, ethionamide, amikacin;
- Duration 12-18 months after culture conversion;
- Often will involve injectable agents, drugs with higher rates of toxicity.

Higher Dose Options

- Clinical breakpoints show "low-dose" or "high-dose" options (i.e. FLQs, INH, ? BDQ):
- Theoretically done to "overcome" mechanisms of resistance;
- Could lead to better penetration or more time above the MICs (i.e. CFZ, LZD);
- Additional monitoring needed for toxicity;
- Should only be done if limited options available.

Drug	High-dose option	Monitoring on high-dose option	Comment
Bedaquiline	500mg loading dose for 14 days followed by 200 mg daily	More frequent monitoring of QTcF interval (i.e. every 14 days)	There are no clear microbiologic breakpoints indicating when higher dose Bdq might be effective. If there is detection of an <i>atpE</i> mutation, then do <u>not</u> use Bdq at any dose.
Clofazimine	300mg daily	More frequent QTcF monitoring, especially if used in combination with other QTcF prolonging drugs	
Isoniazid	10-15mg/kg/day or 15- 20mg/kg/day if used in combination with Cs	Monthly monitoring for peripheral neuropathy	Should give with vitamin B6 (25-75mg daily) to prevent peripheral neuropathy. Do not use if there is a <i>katG</i> mutation detected.
Levofloxacin	20-30mg/kg/day	More frequent QTcF monitoring, especially if used in combination with other QTcF prolonging drugs	
Linezolid	1200mg daily	Complete blood count, visual accuity/color vision screening, and screening for peripheral neuropathy every 14 days	The toxicity of this dose of Lzd has been well established. It should only be used if there are no other options.
Moxifloxacin	12-15mg/kg/day	More frequent QTcF monitoring, especially if used in combination with other QTcF prolonging drugs	



Versporal Increases the Battericidal Activity of Bedaquiline against Mycobacterium tuberpolosu in a Mouse Model

The basic flatter? The sing Sugar State of Asia P.

Arthogolisti in a print gapricost along he discoverences of magnifulary extragrangements, but their arcciments story to rative in Equation, We bound the time conditions recognized with not begund a trade-parties are in contractive. contributed to the action of the feet between the protection to discuss the region of the protection o attraption of general, development of various repeats to the Philadelphia are of respectively providing providing depend indepentation is for provinced therefore inches to desprish below the deviation rather particular.

14-3-20-1-20-2

Brigation de la communicación de la fate de la companie de la comp agreed by the U.S. Fand to Cong Education from the last. In addition of incongregator where of extraord in the life. the paint for the devices of mathematical about the start framework about the parties of large than the paint and the parties of the paint and (MALE) to the Technique Medical Angel Chique angle or for manufacturation of Angelia Chique the first waves place to declare beauty better before the many day or contact company to to a company out Standards and fact edit his till hopder water property and obtained retires practic artists taking stately, balance between expensive and lives wheth above these recents. Desiry that I paid a account access and not the stock, being blothy to the probability of the exployment, destroyment of the control of t the bridge decays in the place and to be other bridges, making the first in the region of the lag. Of common terms the description of the first, he phosp that proteins are provided to the contract the work of a strong conto a stock of the a gardeon figure come of the contact grown to a part outcome for log CV come. stack tecting totagethe del tracilica tecting a factor attempt to ruled in mouth sensor burning reviewers. the deep in the Time, whether the contract to be true of the course, the put want was counted with inchestion or throughly Signalizat scholorosporti, anditi a titi di ac 1019 (faz fai saksaka).

The order office on Prop. Is Moore to plan or plan only to catastrophic bed trained as Devide before otherwise, it's book." many others of the pulse represents a to the extra control of the many designs of the first of the extra control o mal project structural points for art which conflict. Perspecti It six tilling paint in Administration, but has a driver protout in minpolicitud amerianing idea (intra triansled analy, advicated from the rest and to time. It this part, it was allower that with the of the efficie practic of (4), behaviolate by temperative hear the the wind they believe to the control of the behind of the partners. continuous proprieta polici, arresta proprieta de francio. A The photos of several to behalful TI brokens pulseted tion the beginning the destroy of the services of the hybrid service. CRIMA Indiana.

Noticease deviced first approximating facilitation, Ald or repaired to the adults becomes the 100 to the debuttor of the white regimental of subscience of the controls in despressing the cost time common character from The ODC of Andrews regimes A. and a color of \$1.50 more included a gradition by a fall present of Treated thereof into the transform for the problem. colonial in the all your desirates are let all follow recognition and participate creation for Editing of St. Subscriberity, Schepillar and accidents to viscous at equalishma light way produce species and release discovered transactions was principal transport. miles the booking of homosthic actions above officer old-Allowed placement \$1000.700 personne productions, for the surgeon

more and hard at editor to

. We included the witten of heliciphics with the effects compain 6 by lags, some fraction covered total process and profess hape \$550 ments 5000, educations (FD) to be Salton trafficalists has 6.4 (replicable) and or offerences After Prospect Life Suffici for his admirror wheelve take the Will's and SUPs described protestings Will I photo \$1 emplace the decimal special parties. Has been been treating incomes, a short of read print groups (most) print School or Coughy to left title continue by payer. at the 25 for the pleaser of technicities coupled transfer to absente yluter, request on jetra telapitic resopresentation of contract and present at contract at

The belief year building the sensite feet that the course tors should seekly long LPS rinteress to their article on and executive for distinguisher some energy front a tric transfer as 675-761 file you do 600 f week of beings file 110.

transfer to the second second PRESIDENCE AND ADDRESS OF THE PROPERTY OF THE

and the second

Ancillary Medications

- Nutritional support;
- Corticosteroids for meningitis, pericarditis;
- ? Calcium channel blockers to block the efflux pump.



Holistic Packages of Support

- Location of care;
- Mental health services;
- Counseling;
- Nutritional support;
- Transport and finances;
- Transitions in care;
- Palliative care;
- Post-TB lung disease



Special Populations

- At increased risk for these forms of TB (i.e. congregate settings, comorbidities);
- Issues that make dosing or access a challenge (children, pregnancy, substance use);
- Issues of drug penetration (EP-TB);
- Must be included in plans and treatment programs.

Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial





Rodney Dawson, Andreas H Diacon, Veronique De Jager, Kim Narunsky, V Mischka Moodley, Kelly W Stinson, Yongge Liu, Bo Zheng, Jeffrey Hafkin

oa

Background Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive, drug-susceptible pulmonary tuberculosis. Stage 2 of this study was designed to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both versus rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy for 14 days.

Methods Stage 2 of this open-label, active-controlled, randomised, parallel-group study was conducted at two research sites in South Africa in adults (aged 18-64 years) with drug-susceptible pulmonary tuberculosis. Eligible participants had a BMI of 16-32 kg/m² and the ability to produce an adequate volume of sputum (≥10 mL overnight) and were excluded if they had drug-resistant tuberculosis or previous treatment for Mycobacterium tuberculosis within the past 3 years. Participants were centrally randomly assigned via interactive web response technology system, with no stratification, into four treatment groups in a ratio of 14:14:14:4 (quabodepistat 30 mg plus delamanid 300 mg, quabodepistat 30 mg plus bedaquiline 400 mg, or quabodepistat 30 mg plus delamanid 300 mg plus bedaquiline 400 mg orally once daily for 14 days, or rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy [control] according to local standard of care for 20 days). The primary outcomes were safety and tolerability during and after 14 days of treatment in all


November 26, 2024 51473-3099(24)00601-7

https://doi.org/10.1016/ 51473-3099(24)00653-4 Division of Pulmonology

Department of Medicine, University of Cape Town Lung (Prof R Dawson PhD); TASK Applied Science, Cape Town South Africa (A H Diacon MD V De lager MD): University of

Pre-Approval Access

- Multiple novel compounds—although most being tested in treatment shortening trials for DS-TB;
- Quabodepistat furthest along, but also telacebec, ganefeborole, BTZ-043, TBAJ-876. TBAJ-587:
- Rocky history of pre-approval access in TB;
- Much of what we learned about BDQ, LZD, and DLM was through this kind of use.



Toxicity Monitoring and Management

- Using many more toxic, second-line agents, including those that cause permanent disability (i.e. amikacin);
- Monitoring and management MUST be provided, including formal testing free of charge and ancillary medications;
- Shared decision making is essential.



Operational Research

- Common data elements are key to share experiences and generate data that can be used for guidelines even in the absence of RCTs;
- People with TB that has expanded resistance should be involved in setting priorities in this area;
- Should be funded and answer locally relevant questions.



BETTER: Future Work

- Continue to provide support as needed to people living with TB as well as countries/programs;
- As data emerge, practices can be defined;
- Clinical teams available for training and support;
- Advocacy!



Thank you!

jenniferfurin@gmail.com